Effective use of transdermal drug delivery in children

Advanced Drug Delivery Reviews

Volumn 73, Issue , 2014, Pages 63-82

  Delgado Charro, M Begoña ^a   Guy, Richard H ^a  

^a University of Bath   (United Kingdom)

Author keywords

Iontophoresis; Paediatric dosage forms; Premature neonates; Skin; Stratum corneum; Transdermal drug delivery; Transdermal patches

Indexed keywords

DRUG DELIVERY; DRUG DOSAGE; ELECTROPHORESIS; ELECTROTHERAPEUTICS; NEONATAL MONITORING; SKIN;

DOSAGE FORMS; IONTOPHORESIS; PREMATURE NEONATES; STRATUM CORNEUM; TRANSDERMAL DRUG DELIVERY; TRANSDERMAL PATCHES;

PEDIATRICS;

BUPRENORPHINE; CLONIDINE; EMLA; ESTRADIOL; FENCINO; FENTALIS; FENTANYL; LIDOCAINE; LIDOCAINE PLUS TETRACAINE; MATRIFEN; METHYLPHENIDATE; MEZOLAR; NICASSIST; NICOTINE; OSMANIL; SCOPOLAMINE; TILOFYL; TULOBUTEROL; UNCLASSIFIED DRUG; VICTANYL; CAFFEINE; CHLORHEXIDINE GLUCONATE; DEXAMETHASONE; ESTROGEN; ETHINYLESTRADIOL PLUS NORELGESTROMIN; IODINE; NICOTINE PATCH; PLACEBO; PROPYLENE GLYCOL; SELEGILINE; TACROLIMUS; THEOPHYLLINE SODIUM GLYCINATE; DRUG;

ASTHMA; ATTENTION DEFICIT DISORDER; BRONCHITIS; CHILD; CHRONIC BRONCHITIS; CHRONIC PAIN; DRUG DELIVERY SYSTEM; EMPHYSEMA; HUMAN; HYPERSALIVATION; HYPERTENSION; HYPOGONADISM; IN VITRO STUDY; IN VIVO STUDY; IONTOPHORETIC DELIVERY DEVICE; MOTION SICKNESS; NEUROPATHIC PAIN; NONHUMAN; PAIN; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SKIN ABSORPTION; SKIN BARRIER FUNCTION; SKIN FUNCTION; SKIN TOXICITY; TRANSDERMAL DRUG ADMINISTRATION; TRANSDERMAL PATCH; VERTIGO; ABNORMAL DREAMING; ABSENCE OF SIDE EFFECTS; ADRENAL INSUFFICIENCY; APNEA; APPLICATION SITE ERYTHEMA; APPLICATION SITE HYPERPIGMENTATION; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; APPLICATION SITE REACTION; APPLICATION SITE URTICARIA; AREA UNDER THE CURVE; ARTHRALGIA; ATOPIC DERMATITIS; CANCER PAIN; CONTACT DERMATITIS; CONTACT URTICARIA; CONTROLLED CLINICAL TRIAL (TOPIC); CUSHING SYNDROME; DEVICE APPROVAL; DEVICE SAFETY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG LABELING; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; ERYTHRODERMA; EXPERIMENTAL MODEL; FIRST PASS EFFECT; GILLES DE LA TOURETTE SYNDROME; HALLUCINATION; HYPEROSMOLARITY; HYPOTHYROIDISM; JET INJECTOR; JUVENILE RHEUMATOID ARTHRITIS; LACTIC ACIDOSIS; MAXIMUM PLASMA CONCENTRATION; MICRONEEDLE; MYALGIA; NAUSEA; NETHERTON DISEASE; OPIATE ADDICTION; PATIENT COMPLIANCE; PERMEABILITY BARRIER; PHASE 3 CLINICAL TRIAL (TOPIC); PREMATURITY; PRURITUS; RESPIRATION DEPRESSION; SKIN ALLERGY; SKIN MANIFESTATION; SKIN PERMEABILITY; SKIN WATER LOSS; SLEEP DISORDER; SONOPHORESIS; STOMACH PAIN; SUICIDAL BEHAVIOR; TOBACCO DEPENDENCE; TRANSDERMAL DRUG DELIVERY SYSTEM; TURNER SYNDROME; ULTRASOUND; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING; ANIMAL; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; PEDIATRICS; SKIN;

ADMINISTRATION, CUTANEOUS; ANIMALS; CHILD; HUMANS; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; SKIN; SKIN ABSORPTION;

EID: 84902347330     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.11.014     Document Type: Review

References (206)

1. Delgado-Charro M.B., Guy R.H. Transdermal drug delivery. Drug Delivery and Targetting 2001, 207-236. Taylor & Francis, London and New York. A.M. Hillery, A.W. Lloyd, J. Swarbrick (Eds.).
2. Barrett D.A., Rutter N. Transdermal delivery and the premature neonate. Crit. Rev. Ther. Drug 1994, 11:1-30.
3. Watkinson A.C. A commentary on transdermal drug delivery systems in clinical trials. J. Pharm. Sci. 2013, 102:3082-3088.
4. Shwayder T., Akland T. Neonatal skin barrier: structure, function, and disorders. Dermatol. Ther. 2005, 18:87-103.
5. Fluhr J.W., Darlenski R., Taieb A., Hachem J.P., Baudouin C., Msika P., De Belilovsky C., Berardesca E. Functional skin adaptation in infancy-almost complete but not fully competent. Exp. Dermatol. 2010, 19:483-492.
6. Gratieri T., Alberti I., Lapteva M., Kalia Y.N. Next generation intra- and transdermal therapeutic systems: using non- and minimally-invasive technologies to increase drug delivery into and across the skin. Eur. J. Pharm. Sci. 2013, 50:609-622.
7. Chiou Y.B., Blume-Peytavi U. Stratum corneum maturation. A review of neonatal skin function. Skin Pharmacol. Physiol. 2004, 17:57-66.
8. Long C.C., Mills C.M., Finlay A.Y. A practical guide to topical therapy in children. Br. J. Dermatol. 1998, 138:293-296.
9. Stamatas G.N., Nikolovski J., Mack M.C., Kollias N. Infant skin physiology and development during the first years of life: a review of recent findings based on in vivo studies. Int. J. Cosmet. Sci. 2011, 33:17-24.
10. Hardman M.J.B.C. Skin structural development. Skin Barrier 2006, 273-288. Taylor & Francis Group, New York. P.M. Elias, K.R. Feingold (Eds.).
11. Evans N.J., Rutter N. Development of the epidermis in the newborn. Biol. Neonate 1986, 49:74-80.
12. Hardman M.J., Moore L., Ferguson M.W., Byrne C. Barrier formation in the human fetus is patterned. J. Invest. Dermatol. 1999, 113:1106-1113.
13. Kurihara-Bergstrom T., Good W.R., Signor C., Woodwarth M. Epidermal differentiation and permeability in fetal pig skin. Pharm. Res. 1990, 7:1201-1204.
14. Levin J., Maibach H. The correlation between transepidermal water loss and percutaneous absorption: an overview. J. Control. Release 2005, 103:291-299.
15. Aalto-Korte K., Turpeinen M. Transepidermal water loss and absorption of hydrocortisone in widespread dermatitis. Br. J. Dermatol. 1993, 128:633-635.
16. Hammarlund K., Nilsson G.E., Oberg P.A., Sedin G. Transepidermal water loss in newborn infants II. Relation to activity and body temperature. Acta Paediatr. Scand. 1979, 68:371-376.
17. Fanaroff A.A., Wald M., Gruber H.S., Klaus M.H. Insensible water loss in low birth weight infants. Pediatrics 1972, 50:236-245.
18. Williams P.R., Oh W. Effects of radiant warmer on insensible water loss in newborn infants. Am. J. Dis. Child. 1974, 128:511-514.
19. Bell E.F., Neidich G.A., Cashore W.J., Oh W. Combined effect of radiant warmer and phototherapy on insensible water loss in low-birth-weight infants. J. Pediatr. 1979, 94:810-813.
20. Wilson D.R., Maibach H.I. Transepidermal water loss in vivo premature and term infants. Biol. Neonate 1980, 37:180-185.
21. Wu P.Y., Hodgman J.E. Insensible water loss in preterm infants: changes with postnatal development and non-ionizing radiant energy. Pediatrics 1974, 6:704-712.
22. Hammarlund K., Sedin G. Transepidermal water loss in newborn infants IV. Small for gestational age infants. Acta Paediatr. Scand. 1980, 69:377-383.
23. Hammarlund K., Sedin G., Stromberg B. Transepidermal water loss in newborn infants VII. Relation to post-natal age in very pre-term and full-term appropriate for gestational age infants. Acta Paediatr. Scand. 1982, 71:369-374.
24. Hammarlund K., Sedin G., Stromberg B. Transepidermal water loss in newborn infants. VIII. Relation to gestational age and post-natal age in appropriate and small for gestational age infants. Acta Paediatr. Scand. 1983, 72:721-728.
25. Yeh T.F., Amma P., Lilien L.D., Baccaro M.M., Matwynshyn J., Pyati S., Pildes R.S. Reduction of insensible water loss in premature infants under the radiant warmer. J. Pediatr. 1979, 94:651-653.
26. Kalia Y.N., Nonato L.B., Lund C.H., Guy R.H. Development of skin barrier function in premature infants. J. Invest. Dermatol. 1998, 111:320-326.
27. Sedin G., Hammarlund K., Stromberg B. Transepidermal water loss in full-term and pre-term infants. Acta Paediatr. Scand. 1983, 305:27-31.
28. Nachman R.L., Esterly N.B. Increased skin permeability in preterm infants. J. Pediatr. 1971, 79:628-632.
29. Harpin V.A., Rutter N. Barrier properties of the newborn infants skin. J. Pediatr. 1983, 102:419-425.
30. West D.P., Halket J.M., Harvey D.R., Hadgraft J., Solomon L.M., Harper J.I. Percutaneous absorption in preterm infants. Pediatr. Dermatol. 1987, 4:234-237.
31. Afsar F.S. Physiological skin conditions of preterm and term neonates. Clin. Exp. Dermatol. 2010, 35:346-350.
32. Hoeger P.H., Schreiner V., Klaassen I.A., Enzmann C.C., Friedrichs K., Bleck O. Epidermal barrier lipids in human vernix caseosa: corresponding ceramide pattern in vernix and fetal skin. Br. J. Dermatol. 2002, 146:194-201.
33. Visscher M.O., Utturkar R., Pickens W.L., LaRuffa A.A., Robinson M., Wickett R.R., Narendran V., Hoath S.B. Neonatal skin maturation-vernix caseosa and free amino acids. Pediatr. Dermatol. 2011, 28:122-132.
34. Cunico R.L., Maibach H.I., Khan H., Bloom E. Skin barrier properties in the newborn. Transepidermal water loss and carbon dioxide emission rates. Biol. Neonate 1977, 32:177-182.
35. Hammarlund K., Nilsson G.E., Oberg P.A., Sedin G. Transepidermal water loss in newborn infants I. Relation to ambient humidity and site of measurement and estimation of total transepidermal water loss. Acta Paediatr. Scand. 1977, 66:553-562.
36. Kelleher M.M., O'Carroll M., Gallagher A., Murray D.M., Dunn Galvin A., Irvine A.D., Hourihane J.O. Newborn transepidermal water loss values: a reference dataset. Pediatr. Dermatol. 2013, 30:712-716.
37. Farahmand S., Tien L., Hui X., Maibach H.I. Measuring transepidermal water loss: a comparative in vivo study of condenser-chamber, unventilated-chamber and open-chamber systems. Skin Res. Technol. 2009, 15:392-398.
38. Imhof R.E., De Jesus M.E., Xiao P., Ciortea L.I., Berg E.P. Closed-chamber transepidermal water loss measurement: microclimate, calibration and performance. Int. J. Cosmet. Sci. 2009, 31:97-118.
39. Abe T. Studies on skin surface barrier functions. Transepidermal water loss and skin surface lipids during childhood. Chem. Pharm. Bull. 1978, 26:1659-1665.
40. Tachi M., Iwamori M. Mass spectrometric characterization of cholesterol esters and wax esters in epidermis of fetal, adult and keloidal human skin. Exp. Dermatol. 2008, 17:318-323.
41. Giusti F., Martella A., Bertoni L., Seidenari S. Skin barrier, hydration, and pH of the skin of infants under 2years of age. Pediatr. Dermatol. 2001, 18:93-96.
42. Hoeger P.H., Enzmann C.C. Skin physiology of the neonate and young infant: a prospective study of functional skin parameters during early infancy. Pediatr. Dermatol. 2002, 19:256-262.
43. Fluhr J.W., Darlenski R., Lachmann N., Baudouin C., Msika P., De Belilovsky C., Hachem J.P. Infant epidermal skin physiology: adaptation after birth. Br. J. Dermatol. 2012, 166:483-490.
44. Nikolovski J., Stamatas G.N., Kollias N., Wiegand B.C. Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. J. Invest. Dermatol. 2008, 128:1728-1736.
45. Minami-Hori M., Honma M., Fujii M., Nomura W., Kanno K., Hayashi T., Nakamura E., Nagaya K., Miyauchi Y., Fujimura T., Hotta M., Takagi Y., Kitahara T., Takema Y., Iizuka H. Developmental alterations of physical properties and components of neonatal-infantile stratum corneum of upper thighs and diaper-covered buttocks during the 1st year of life. J. Dermatol. Sci. 2013, 73:67-73. 10.1016/j.jdermsci.2013.08.015.
46. Michel M., L'Heureux N., Auger F.A., Germain L. From newborn to adult: phenotypic and functional properties of skin equivalent and human skin as a function of donor age. J. Cell. Physiol. 1997, 171:179-189.
47. Potts R.O., Guy R.H. Predicting skin permeability. Pharm. Res. 1992, 9:663-669.
48. Turner N.G., Guy R.H. Iontophoretic transport pathways: dependence on penetrant physicochemical properties. J. Pharm. Sci. 1997, 86:1385-1389.
49. Neri I., Piccolo V., Cocchi G., Starace M., Patrizi A., Dika E., Piraccini B.M. Hair in newborns and infants: clinical and dermoscopic evaluation of 45 cases. Br. J. Dermatol. 2013, 169:896-900.
50. Otberg N., Richter H., Schaefer H., Blume-Peytavi U., Sterry W., Lademann J. Variations of hair follicle size and distribution in different body sites. J. Invest. Dermatol. 2004, 122:14-19.
51. Blume-Peytavi U., Massoudy L., Patzelt A., Lademann J., Dietz E., Rasulev U., Garcia Bartels N. Follicular and percutaneous penetration pathways of topically applied minoxidil foam. Eur. J. Pharm. Biopharm. 2010, 76:450-453.
52. Mackay P.M., Millar M.R., Levene M.I., Hoy C.M., Dealler S.F., Papouli M., Ng P.C. Development of the transdermal potential of human skin. Pediatr. Res. 1991, 29:78-81.
53. Micali G., Bhatt R.H., Distefano G., Caltabiano L., Cook B., Fischer J.H., Solomon L.M., West D.P. Evaluation of transdermal theophylline pharmacokinetics in neonates. Pharmacotherapy 1993, 13:386-390.
54. Amato M., Isenschmid M., Huppi P. Percutaneous caffeine application in the treatment of neonatal apnoea. Eur. J. Pediatr. 1991, 150:592-594.
55. Evans N.J., Rutter N., Hadgraft J., Phil D., Parr G. Percutaneous administration of theophylline in the preterm infant. J. Pediatr. 1985, 107:307-311.
56. Cartwright R.G., Cartlidge P.H., Rutter N., Melia C.D., Davis S.S. Transdermal delivery of theophylline to premature infants using a hydrogel disc system. Br. J. Clin. Pharmacol. 1990, 29:533-539.
57. Morisot C., Simoens C., Trublin F., Lhermitte M., Gremillet C., Robert M.H., Lequien P. Efficacy of percutaneous caffeine in the treatment of apnea in the premature infant. Arch. Fr. Pediatr. 1990, 47:221-224.
58. Amato M., Huppi P., Isenschmid M., Schneider H. Developmental aspects of percutaneous caffeine absorption in premature infants. Am. J. Perinatol. 1992, 9:431-434.
59. BNF for Children Medicines Complete 2003, The Pharmaceutical Press.
60. Taketomo C.K., Hodding J.H., K.D.M. Pediatric & Neonatal Dosage Handbook 2012-13, Walters &Kluwer Health, Hudson, APhA, LexicompTM. 19th ed.
61. Vaksmann G., Rey C., Dupuis C. Percutaneous trinitrine to facilitate access to the peripheral venous system in infants. Arch. Fr. Pediatr. 1989, 46:623-625.
62. Lenoir P., Segers M., Ramet J. Transdermal trinitrine therapy in the pediatric age group-considerations about the local application of trinitrine ointment as an aid to venopuncture. Pediatrie 1990, 45:515-517.
63. Verma P.S., Singal A., Yadav P. Perniosis in an infant treated with topical nitroglycerin. Pediatr. Dermatol. 2013, 130:623-624.
64. Wong A.F., McCulloch L.M., Sola A. Treatment of peripheral tissue ischemia with topical nitroglycerin ointment in neonates. J. Pediatr. 1992, 121:980-983.
65. Agyralides G.G., Dallas P.P., Rekkas D.M. Development and in vitro evaluation of furosemide transdermal formulations using experimental design techniques. Int. J. Pharm. 2004, 281:35-43.
66. Sintov A.C., Krymberk I., Gavrilov V., Gorodischer R. Transdermal delivery of paracetamol for paediatric use: effects of vehicle formulations on the percutaneous penetration. J. Pharm. Pharmacol. 2003, 55:911-919.
67. Bonina F.P., Montenegro L., Micali G., West D.P., Palicharla P., Koch R.L. In-vitro percutaneous-absorption evaluation of phenobarbital through hairless mouse, adult and premature human skin. Int. J. Pharm. 1993, 98:93-99.
68. Barrett D.A., Rutter N., Davis S.S. An in vitro study of diamorphine permeation through premature human neonatal skin. Pharm. Res. 1993, 10:583-587.
69. Delgado-Charro M.B. Sampling substrates by skin permeabilization. Dermatokinetics of Therapeutic Agents 2011, 149-174. Taylor and Francis Publishers, Boca Raton. M. Murthy (Ed.).
70. Murphy M.G., Peck C.C., Conner D.P., Zamani K., Merenstein G.B., Rodden D. Transcutaneous theophylline collection in preterm infants. Clin. Pharm. Ther. 1990, 47:427-434.
71. Sekkat N., Naik A., Kalia Y.N., Glikfeld P., Guy R.H. Reverse iontophoretic monitoring in premature neonates: feasibility and potential. J. Control. Release 2002, 81:83-89.
72. Curley A., Kimbrough R.D., Hawk R.E., Nathenson G., Finberg L. Dermal absorption of hexochlorophane in infants. Lancet 1971, 2:296-297.
73. Linder N., Prince S., Barzilai A., Keller N., Klinger G., Shalit I., Prince T., Sirota L. Disinfection with 10% povidone-iodine versus 0.5% chlorhexidine gluconate in 70% isopropanol in the neonatal intensive care unit. Acta Paediatr. 2004, 93:205-210.
74. Barakat M., Carson D., Hetherton A.M., Smyth P., Leslie H. Hypothyroidism secondary to topical iodine treatment in infants with spina bifida. Acta Paediatr. 1994, 83:741-743.
75. AvRuskin T.W., Greenfield E., Prasad V., Greig F., Juan C.S. Decreased T3 and T4 levels following topical application of povidone-iodine in premature neonates. J. Pediatr. Endocrinol. 1994, 7:205-209.
76. Aitken J., Williams F.L.R. A systematic review of thyroid dysfunction in preterm neonates exposed to topical iodine. Arch. Dis. Child. Fetal Neonatal 2013, 303799. 10.1136/archdischild.
77. Harpin V., Rutter N. Percutaneous alcohol absorption and skin necrosis in a preterm infant. Arch. Dis. Child. 1982, 57:477-479.
78. Chapman A.K., Aucott S.W., Milstone A.M. Safety of chlorhexidine gluconate used for skin antisepsis in the preterm infant. J. Perinatol. 2012, 32:4-9.
79. Gongwer L.E., Hubben K., Lenkiewicz R.S., Hart E.R., Cockrell B.Y. The effects of daily bathing of neonatal rhesus monkeys with an antimicrobial skin cleanser containing chlorhexidine gluconate. Toxicol. Appl. Pharmacol. 1980, 52:255-261.
80. Cowen J., Ellis S.H., Mcainsh J. Absorption of chlorhexidine from the intact skin of newborn-infants. Arch. Dis. Child. 1979, 54:379-383.
81. Aggett P.J., Cooper L.V., Ellis S.H., McAinsh J. Percutaneous absorption of chlorhexidine in neonatal cord care. Arch. Dis. Child. 1981, 56:878-880.
82. O'Neill J., Hosmer M., Challop R., Driscoll J., Speck W., Sprunt K. Percutaneous absorption potential of chlorhexidine in neonates. Curr. Ther. Res. 1982, 31:485-489.
83. Bringue Espuny X., Soria X., Sole E., Garcia J., Marco J.J., Ortega J., Ortiz M., Pueyo A. Chlorhexidine-methanol burns in two extreme preterm newborns. Pediatr. Dermatol. 2010, 27:676-678.
84. Chapman A.K., Aucott S.W., Gilmore M.M., Advani S., Clarke W., Milstone A.M. Absorption and tolerability of aqueous chlorhexidine gluconate used for skin antisepsis prior to catheter insertion in preterm neonates. J. Perinatol. 2013, 33:768-771.
85. Peleg O., Bar-Oz B., Arad I. Coma in a premature infant associated with the transdermal absorption of propylene glycol. Acta Paediatr. 1998, 87:1195-1196.
86. American Academy of Pediatrics Committee on Drugs "Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics 1997, 99:268-278.
87. Kulo A., de Hoon J.N., Allegaert K. The propylene glycol research project to illustrate the feasibility and difficulties to study toxicokinetics in neonates. Int. J. Pharm. 2012, 435:112-114.
88. Nahata M.C. Safety of "inert" additives or excipients in paediatric medicines. Arch. Dis. Child. Fetal 2009, 94:F392-F393.
89. Kulo A., Smits A., Naulaers G., de Hoon J., Allegaert K. Biochemical tolerance during low dose propylene glycol exposure in neonates: a formulation-controlled evaluation. DARU J. Pharm. Sci. 2012, 10.1186/1560-8115-20-5.
90. McCollum A.D., Paik A., Eichenfield L.F. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatr. Dermatol. 2010, 27:425-436.
91. Allen A., Siegfried E., Silverman R., Williams M.L., Elias P.M., Szabo S.K., Korman N.J. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch. Dermatol. 2001, 137:747-750.
92. Keipert J.A. The absorption of topical corticosteroids with particular reference to percutaneous absorption in infancy and childhood. Med. J. Aust. 1971, 1:1021-1025.
93. Turpeinen M., Salo O.P., Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br. J. Dermatol. 1986, 115:475-484.
94. Turpeinen M., Lehtokoskilehtiniemi E., Leisti S., Salo O.P. Percutaneous-absorption of hydrocortisone during and after the acute phase of dermatitis in children. Pediatr. Dermatol. 1988, 5:276-279.
95. Feiwel M., James V.H., Barnett E.S. Effect of potent topical steroids on plasma-cortisol levels of infants and children with eczema. Lancet 1969, 1:485-487.
96. Feinblatt B.J., Aceto T., Beckhorn G., Bruck E. Percutaneous absorption of hydrocortisone in children. Am. J. Dis. Child. 1966, 112:218-224.
97. Turpeinen M. Absorption of hydrocortisone from the skin reservoir in atopic dermatitis. Br. J. Dermatol. 1991, 124:358-360.
98. Calhoun D.A., Murthy S.N., Bryant B.G., Luedtke S.A., Bhatt-Mehta V. Recent advances in neonatal pharmacotherapy. Ann. Pharmacother. 2006, 40:710-719.
99. Weinberger B., Hanna N., Gropper C.A., Heck D.E., Laskin D.L., Laskin J.D. Transdermal xenobiotics in newborn skin. J. Toxicol. Cutan. Ocul. 2003, 22:51-67.
100. Evans N.J., Guy R.H., Hadgraft J., Parr G.D., Rutter N. Transdermal drug delivery to neonates. Int. J. Pharm. 1985, 24:259-266.
101. Plantin P., Jouan N., Karangwa A., Gavanou J., Cauvin J.M., Schollhammer M., Sizun J., Guillois B., Sassolas B., Collet M., Guillet G. Variations of the skin permeability in premature newborn infants. Value of the skin vasoconstriction test with neosynephrine. Arch. Fr. Pediatr. 1992, 49:623-625.
102. Sekkat N., Kalia Y.N., Guy R.H. Development of an in vitro model for premature neonatal skin: biophysical characterization using transepidermal water loss. J. Pharm. Sci. 2004, 93:2936-2940.
103. Sekkat N., Kalia Y.N., Guy R.H. Porcine ear skin as a model for the assessment of transdermal drug delivery to premature neonates. Pharm. Res. 2004, 21:1390-1397.
104. Djabri A., Guy R.H., Delgado-Charro M.B. Transdermal iontophoresis of ranitidine: an opportunity in paediatric drug therapy. Int. J. Pharm. 2012, 435:27-32.
105. Djabri A., Guy R.H., Delgado-Charro M.B. Passive and iontophoretic transdermal delivery of phenobarbital: implications in paediatric therapy. Int. J. Pharm. 2012, 435:76-82.
106. Delgado-Charro M.B. Recent advances on transdermal iontophoretic drug delivery and non-invasive sampling. J. Drug Deliv. Sci. Technol 2009, 19:75-88.
107. Nachum Z., Shupak A., Gordon C.R. Transdermal scopolamine for prevention of motion sickness-clinical pharmacokinetics and therapeutic applications. Clin. Pharmacokinet. 2006, 45:543-566.
108. Apfel C.C., Zhang K., George E., Shi S., Jalota L., Hornuss C., Fero K.E., Heidrich F., Pergolizzi J.V., Cakmakkaya O.S., Kranke P. Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis. Clin. Ther. 2010, 32:1987-2002.
109. Doyle E., Byers G., McNicol L.R., Morton N.S. Prevention of postoperative nausea and vomiting with transdermal hyoscine in children using patient-controlled analgesia. Br. J. Anaesth. 1994, 72:72-76.
110. Healy F., Panitch H.B. Pulmonary complications of pediatric neurological diseases. Pediatr. Ann. 2010, 39:216-224.
111. Rapoport A. Sublingual atropine drops for the treatment of pediatric sialorrhea. J. Pain Symptom Manag. 2010, 40:783-788.
112. Horimoto Y., Tomie H., Hanzawa K., Nishida Y. Scopolamine patch reduces postoperative emesis in pediatric-patients following strabismus surgery. Can. J. Anaesth. 1991, 38:441-444.
113. Lin Y.C. Anisocoria from transdermal scopolamine. Paediatr. Anaesth. 2001, 11:626-627.
114. Paut O., Camboulives J., Viard L., Lemoing J.P., Levron J.C. Pharmacokinetics of transdermal fentanyl in the peri-operative period in young children. Anaesthesia 2000, 55:1202-1207.
115. Twycross R., Prommer E.E., Mihalyo M., Wilcock A. Fentanyl (transmucosal). J. Pain Symptom Manag. 2012, 44:131-149.
116. Geary T., Negus A., Anderson B.J., Zernikow B. Perioperative management of the child on long-term opioids. Pediatr. Anesth. 2012, 22:189-202.
117. Hunt A., Goldman A., Devine T., Phillips M. Transdermal fentanyl for pain relief in a paediatric palliative care population. Palliat. Med. 2001, 15:405-412.
118. U.S.Food and Drug Administration Drugs@FDA database Last accessed. http://www.fda.gov/Drugs/InformationOnDrugs/ucm135821.htm.
119. Zernikow B., Michel E., Anderson B. Transdermal fentanyl in childhood and adolescence: a comprehensive literature review. J. Pain 2007, 8:187-207.
120. Collins J.J., Dunkel I.J., Gupta S.K., Inturrisi C.E., Lapin J., Palmer L.N., Weinstein S.M., Portenoy R.K. Transdermal fentanyl in children with cancer pain: Feasibility, tolerability, and pharmacokinetic correlates. J. Pediatr. 1999, 134:319-323.
121. Hunt R.D. Treatment effects of oral and transdermal clonidine in relation to methylphenidate: an open pilot study in ADD-H. Psychopharmacol. Bull. 1987, 23:111-114.
122. Finkel J.C., Finley A., Greco C., Weisman S.J., Zeltzer L. Transdermal fentanyl in the management of children with chronic severe pain-results from an international study. Cancer 2005, 104:2847-2857.
123. Datapharm, Electronic Medicines Compendium Last accessed. http://www.medicines.org.uk/emc/.
124. Hunt R.D., Capper L., O'Connell P. Clonidine in child and adolescent psychiatry. J. Child Adolesc. Psychopharmacol. 1990, 1:87-102.
125. Broderick-Cantwell J.J. Case study: accidental clonidine patch overdose in attention-deficit/hyperactivity disorder patients. J. Am. Acad. Child Psychiatry 1999, 38:95-98.
126. Harris J.M. Clonidine patch poxicity. Dicp Ann. Pharmacother. 1990, 24:1191-1194.
127. Deutsch E.S., Nadkarni V.M. Clonidine prophylaxis for narcotic and sedative withdrawal syndrome following laryngotracheal reconstruction. Arch. Otolaryngol. 1996, 122:1234-1238.
128. Zawaideh M.A., Duncan B., Joseph M.W., Dixit M.P. Treatment of chronic hypertension with intravenous enalaprilat and transdermal clonidine. Pediatr. Nephrol. 2001, 16:85-86.
129. Connor D.F., Fletcher K.E., Swanson J.M. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J. Am. Acad. Child Psychiatry 1999, 38:1551-1559.
130. Duong S., Chung K., Wigal S.B. Metabolic, toxicological, and safety considerations for drugs used to treat ADHD. Expert Opin. Drug Metab. 2012, 8:543-552.
131. Anderson V.R., Scott L.J. Methylphenidate transdermal system-in attention-deficit hyperactivity disorder in children. Drugs 2006, 66:1117-1126.
132. Elia J., Wilson Z., La Porta L.S., Algon S.A., Prowler M.L., Cartwright S.T., McKenna P.A., Laracy S., Takeda T., Borgmann-Winter K. Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder. Expert. Rev. Clin. Pharmacol. 2011, 4:311-328.
133. Patrick K.S., Straughn A.B., Perkins J.S., Gonzalez M.A. Evolution of stimulants to treat ADHD: transdermal methylphenidate. Hum. Psychopharmacol. 2009, 24:1-17.
134. Pierce D., Dixon C.M., Wigal S.B., McGough J.J. Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. J. Child Adolesc. Psychopharmacol. 2008, 18:355-364.
135. Bukstein O.G. Transdermal methylphenidate system: old wine in a new bottle. Expert Opin. Drug Metab. Toxicol. 2009, 5:661-665.
136. May D.E., Kratochvil C.J. Attention-deficit hyperactivity disorder recent advances in paediatric pharmacotherapy. Drugs 2010, 70:15-40.
137. Pierce D., Katic A., Buckwalter M., Webster K. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. J. Clin. Psychopharmacol. 2010, 30:554-564.
138. Warshaw E.M., Paller A.S., Fowler J.F., Zirwas M.J. Practical management of cutaneous reactions to the methylphenidate transdermal system: recommendations from a dermatology expert panel consensus meeting. Clin. Ther. 2008, 30:326-337.
139. Findling R.L., Wigal S.B., Bukstein O.G., Boellner S.W., Abikoff H.B., Turnbow J.M., Civil R. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin. Ther. 2009, 31:1844-1855.
140. Wilens T.E., Boellner S.W., Lopez F.A., Turnbow J.M., Wigal S.B., Childress A.C., Abikoff H.B., Manos M.J. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 2008, 47:700-708.
141. Ghuman J.K., Byreddy S., Ghuman H.S. Methylphenidate transdermal system in preschool children with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2011, 21:495-498.
142. Michel E., Anderson B.J., Zernikow B. Buprenorphine TTS for children-a review of the drug's clinical pharmacology. Pediatr. Anesth. 2011, 21:280-290.
143. Prapaitrakool S., Hollmann M.W., Wartenberg H.C., Preckel B., Brugger S. Use of buprenorphine in children with chronic pseudoobstruction syndrome case series and review of literature. Clin. J. Pain 2012, 28:722-725.
144. Ruggiero A., Coccia P., Arena R., Maurizi P., Battista A., Ridola V., Attina G., Riccardi R. Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain. Pediatr. Blood Cancer 2013, 60:433-437.
145. Ichikawa I.S., H. Long-term safety, efficacy, and patient acceptability of the tulobuterol patch. Res. Rep. Transdermal Drug Deliv. 2013, 3:9-18.
146. Iikura Y., Uchiyama H., Akimoto K., Ebisawa M., Sakaguchi N., Tsubaki T., Ishizu H., Kabayama H., Yagi K., Miura K. Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. Ann. Allergy Asthma Immunol. 1995, 74:147-151.
147. Ankarberg-Lindgren C., Elfving M., Wikland K.A., Norjavaara E. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J. Clin. Endocrinol. Metab. 2001, 86:3039-3044.
148. Kenigsberg L., Balachandar S., Prasad K., Shah B. Exogenous pubertal induction by oral versus transdermal estrogen therapy. J. Pediatr. Adolesc. Gynecol. 2013, 26:71-79.
149. Nabhan Z.M., DiMeglio L.A., Qi R., Perkins S.M., Eugster E.A. Conjugated oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study. J. Clin. Endocrinol. Metab. 2009, 94:2009-2014.
150. Nabhan Z.M., Eugster E.A. Medical care of girls with Turner syndrome: where are we lacking?. Endocr. Pract. 2011, 17:747-752.
151. Langley T.E., Huang Y., Lewis S., McNeill A., Coleman T., Szatkowski L. Prescribing of nicotine replacement therapy to adolescents in England. Addiction 2011, 106:1513-1519.
152. Dalton W.T., Klesges L.M., Henderson L., Somes G., Robinson L., Johnson K.C. Gender, smoking status, and risk behavior attitudes explain adolescents' patterns of nicotine replacement therapy use. Addict. Behav. 2010, 35:147-151.
153. Robinson L.A., Emmons K.M., Moolchan E.T., Ostroff J.S. Developing smoking cessation programs for chronically ill teens: Lessons learned from research with healthy adolescent smokers. J. Pediatr. Psychol. 2008, 33:133-144.
154. Kim Y., Myung S.K., Jeon Y.J., Lee E.H., Park C.H., Seo H.G., Huh B.Y. Effectiveness of pharmacologic therapy for smoking cessation in adolescent smokers: Meta-analysis of randomized controlled trials. Am. J. Health Syst. Pharm. 2011, 68:219-226.
155. Hanson K., Allen S., Jensen S., Hatsukami D. Treatment of adolescent smokers with the nicotine patch. Nicotin Tob. Res. 2003, 5:515-526.
156. Shytle R.D., Silver A.A., Philipp M.K., McConville B.J., Sanberg P.R. Transdermal nicotine for Tourette's syndrome. Drug Dev. Res. 1996, 38:290-298.
157. Reed M., Findling R., Greenhill L., Sallee F.R., Conners K., Blumer J. Pharmacokinetics (PK) effectiveness (E) and tolerability (T) of transdermal selegiline (STS) in children (C) and adolescents (A) with attention deficit hyperactivity disorder (ADHD). Clin. Pharmacol. Ther. 2003, 73. (P28-P28).
158. Logsdon S., Richards J., Omar H.A. Long-term evaluation of the use of the transdermal contraceptive patch in adolescents. Sci. World J. 2004, 4:512-516.
159. Zempsky W.T., Anand K.J.S., Sullivan K.M., Fraser D., Cucina K. Lidocaine iontophoresis for topical anesthesia before intravenous line placement in children. J. Pediatr. 1998, 132:1061-1063.
160. Squire S.J., Kirchhoff K.T., Hissong K. Comparing two methods of topical anesthesia used before intravenous cannulation in pediatric patients. J. Pediatr. Health Care 2000, 14:68-72.
161. Galinkin J.L., Rose J.B., Harris K., Watcha M.F. Lidocaine iontophoresis versus eutectic mixture of local anesthetics (EMLA®) for IV placement in children. Anesth. Analg. 2002, 94:1484-1488.
162. Rose J.B., Galinkin J.L., Jantzen E.C., Chiavacci R.M. A study of lidocaine iontophoresis for pediatric venipuncture. Anesth. Analg. 2002, 94:867-871.
163. Zeltzer L., Regalado M., Nichter L.S., Barton D., Jennings S., Pitt L. Iontophoresis versus subcutaneous injection-a comparison of 2 methods of local-anesthesia delivery in children. Pain 1991, 44:73-78.
164. Kearns G.L., Heacook J., Daly S.J., Singh H., Alander S.W., Qu S. Percutaneous lidocaine administration via a new iontophoresis system in children: tolerability and absence of systemic bioavailability. Pediatrics 2003, 112:578-582.
165. Mudry B., Carrupt P.A., Guy R.H., Delgado-Charro M.B. Quantitative structure-permeation relationship for iontophoretic transport across the skin. J. Control. Release 2007, 122:165-172.
166. U.S.National Institute of Health ClinicalTrials.gov Last accesed. http://clinicaltrials.gov/ct2/home.
167. Mina R., Melson P., Powell S., Rao M., Hinze C., Passo M., Graham T.B., Brunner H.I. Effectiveness of dexamethasone iontophoresis for temporomandibular joint involvement in juvenile idiopathic arthritis. Arthritis Care Res. 2011, 63:1511-1516.
168. Singh P., Boniello S., Liu P., Dinh S. Transdermal iontophoretic delivery of methylphenidate HCl in vitro. Int. J. Pharm. 1999, 178:121-128.
169. Eastman R.C., Chase H.P., Buckingham B., Hathout E.H., Fuller-Byk L., Leptien A., Van Wyhe M.M., Davis T.L., Fermi S.J., Pechler H., Sahyun G., Lopatin M., Wang B.Y., Wei C., Bartkowiak M., Ginsberg B.H., Tamada J.A., Pitzer K.R. Use of the GlucoWatch biographer in children and adolescents with diabetes. Pediatr. Diabetes 2002, 3:127-134.
170. Accuracy of the GlucoWatch G2 Biographer and the continuous glucose monitoring system during hypoglycemia-experience of the diabetes research in children network. Diabetes Care 2004, 27:722-726. The Diabetes Research in Children Network (DirectNet) Study Group.
171. Djabri A., van't Hoff W., Brock P., Wong I.C.K., Guy R.H., Delgado-Charro M.B. Non-invasive assessment of renal function via transdermal reverse iontophoresis of iohexol: A pilot study. Ther. Drug Monit. 2009, 31. (617-617).
172. Sethna N.F., Verghese S.T., Hannallah R.S., Solodiuk J.C., Zurakowski D., Berde C.B. A randomized controlled trial to evaluate S-Caine patch for reducing pain associated with vascular access in children. Anesthesiology 2005, 102:403-408.
173. Croxtall J.D. Lidocaine/Tetracaine medicated plaster in minor dermatological and needle puncture procedures. Drugs 2010, 70:2113-2120.
174. ®) for topical anaesthesia before vascular access. Br. J. Anaesth. 2009, 102:210-215.
175. Masud S., Wasnich R.D., Ruckle J.L., Garland W.T., Halpern S.W., Mee-Lee D., Ashburn M.A., Campbell J.C. Contribution of a heating element to topical anesthesia patch efficacy prior to vascular access: results from two randomized, double-blind studies. J. Pain Symptom Manag. 2010, 40:510-519.
176. Singer A.J., Taira B.R., Chisena E.N., Gupta N., Chipley J. Warm lidocaine/tetracaine patch versus placebo before pediatric intravenous cannulation: a randomized controlled trial. Ann. Emerg. Med. 2008, 52:41-47.
177. Soltesz S., Dittrich K., Teschendorf P., Fuss I., Molter G. Topical anesthesia before vascular access in children. Anaesthesist 2010, 59:519-523.
178. Chang P.C., Goresky G.V., O'Connor G., Pyesmany D.A., Rogers P.C., Steward D.J., Stewart J.A. A multicentre randomized study of single-unit dose package of EMLA patch vs EMLA 5% cream for venepuncture in children. Can. J. Anaesth. 1994, 41:59-63.
179. Cassidy K.L., Reid G.J., McGrath P.J., Smith D.J., Brown T.L., Finley G.A. A randomized double-blind, placebo-controlled trial of the EMLA patch for the reduction of pain associated with intramuscular injection in four to six-year-old children. Acta Paediatr. 2001, 90:1329-1336.
180. Halperin B.A., Halperin S.A., McGrath P., Smith B., Houston T. Use of lidocaine-prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate and hepatitis B vaccines in infants from birth to six months of age. Pediatr. Infect. Dis. J. 2002, 21:399-405.
181. Halperin S.A., McGrath P., Smith B., Houston T. Lidocaine-prilocaine patch decreases the pain associated with the subcutaneous administration of measles-mumps-rubella vaccine but does not adversely affect the antibody response. J. Pediatr. 2000, 136:789-794.
182. de Waard-van der Spek F.B., Mulder P.G., Oranje A.P. Prilocaine/lidocaine patch as a local premedication for skin biopsy in children. J. Am. Acad. Dermatol. 1997, 37:418-421.
183. Calamandrei M., Messeri A., Busoni P., Bernini G., Lippi A., Tucci F. Comparison of two application techniques of EMLA and pain assessment in pediatric oncology patients. Reg. Anesth. 1996, 21:557-560.
184. Nilsson A., Boman I., Wallin B., Rotstein A. The EMLA patch-a new type of local anaesthetic application for dermal analgesia in children. Anaesthesia 1994, 49:70-72.
185. Kim C.H., Yoon J.U., Lee H.J., Shin S.W., Yoon J.Y., Byeon G.J. Availability of a 5% lidocaine patch used prophylactically for venipuncture- or injection-related pain in children. J. Anesth. 2012, 26:552-555.
186. Shah U.U., Roberts M., Gul M.O., Tuleu C., Beresford M.W. Needle-free and microneedle drug delivery in children: A case for disease-modifying antirheumatic drugs (DMARDs). Int. J. Pharm. 2011, 416:1-11.
187. Mitragotri S. Immunization without needles. Nat. Rev. Immunol. 2005, 5:905-916.
188. Cazares-Delgadillo J., Ganem-Rondero A., Kalia Y.N. Human growth hormone: new delivery systems, alternative routes of administration, and their pharmacological relevance. Eur. J. Pharm. Biopharm. 2011, 78:278-288.
189. Resik S., Tejeda A., Lago P.M., Diaz M., Carmenates A., Sarmiento L., Alemani N., Galindo B., Burton A., Friede M., Landaverde M., Sutter R.W. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J. Infect. Dis. 2010, 201:1344-1352.
190. Silverstein J.H., Murray F.T., Malasanos T., Myers S., Johnson S.B., Frye K., Grossman M. Clinical testing results and high patient satisfaction with a new needle-free device for growth hormone in young children. Endocrine 2001, 15:15-17.
191. Migdal M., Chudzynska-Pomianowska E., Vause E., Henry E., Lazar J. Rapid, needle-free delivery of lidocaine for reducing the pain of venipuncture among pediatric subjects. Pediatrics 2005, 115:e393-e398.
192. Zempsky W.T., Bean-Lijewski J., Kauffman R.E., Koh J.L., Malviya S.V., Rose J.B., Richards P.T., Gennevois D.J. Needle-free powder lidocaine delivery system provides rapid effective analgesia for venipuncture or cannulation pain in children: randomized, double-blind comparison of venipuncture and venous cannulation pain after fast-onset needle-free powder lidocaine or placebo treatment trial. Pediatrics 2008, 121:979-987.
193. Jimenez N., Bradford H., Seidel K.D., Sousa M., Lynn A.M. A comparison of a needle-free injection system for local anesthesia versus EMLA for intravenous catheter insertion in the pediatric patient. Anesth. Analg. 2006, 102:411-414.
194. Donnelly R.F., Raj Singh T.R., Woolfson A.D. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv. 2010, 17:187-207.
195. Garland M.J., Migalska K., Mahmood T.M., Singh T.R., Woolfson A.D., Donnelly R.F. Microneedle arrays as medical devices for enhanced transdermal drug delivery. Expert Rev. Med. Devices 2011, 8:459-482.
196. Al-Zahrani S., Zaric M., McCrudden C., Scott C., Kissenpfennig A., Donnelly R.F. Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy. Expert Opin. Drug Deliv. 2012, 9:541-550.
197. Cormier M., Johnson B., Ameri M., Nyam K., Libiran L., Zhang D.D., Daddona P. Transdermal delivery of desmopressin using a coated microneedle array patch system. J. Control. Release 2004, 97:503-511.
198. Gupta J., Felner E.I., Prausnitz M.R. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol. Ther. 2011, 13:451-456.
199. Norman J.J., Brown M.R., Raviele N.A., Prausnitz M.R., Felner E.I. Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes. Pediatr. Diabetes 2013, 14:459-465.
200. Ploin D., Schwarzenbach F., Dubray C., Nicolas J.F., Goujon C., Trong M.D., Laurent P.E. Echographic measurement of skin thickness in sites suitable for intradermal vaccine injection in infants and children. Vaccine 2011, 29:8438-8442.
201. Singer A.J., Weeks R., Regev R. Laser-assisted anesthesia reduces the pain of venous cannulation in children and adults: a randomized controlled trial. Acad. Emerg. Med. 2006, 13:623-628.
202. ® cream application for pain relief prior to intravenous cannulation. Eur. J. Pediatr. 2012, 171:985-988.
203. Parekh D., Miller M.A., Borys D., Patel P.R., Levsky M.E. Transdermal patch medication delivery systems and pediatric poisonings, 2002-2006. Clin. Pediatr. 2008, 47:659-663.
204. Tanner T., Marks R. Delivering drugs by the transdermal route: review and comment. Skin Res. Technol. 2008, 14:249-260.
205. Wokovich A.M., Prodduturi S., Doub W.H., Hussain A.S., Buhse L.F. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur. J. Pharm. Biopharm. 2006, 64:1-8.
206. Oliveira G., Hadgraft J., Lane M.E. Toxicological implications of the delivery of fentanyl from gel extracted from a commercial transdermal reservoir patch. Toxicol. in Vitro 2012, 26:645-648.